Loading
NASDAQHealthcareBiotechnology
Latest quote
$7.04
+$0.28 · +4.14%
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Previous close
$7.04
+$0.28 · +4.14%
Regular session · ET · Market data may be delayed.
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Day range
Current $7.04
52-week range
Current $7.04
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
49
Fair Value
Sentiment
42
Mixed
Risk
86
Extreme Risk
Momentum
35
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Day range
Current $7.04
52-week range
Current $7.04
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 116.59M USD | 105.76M USD | 113.45M USD | 102.29M USD | 7.34M USD |
| Cost of goods sold | 5.42M USD | 3.88M USD | 4.64M USD | 4.79M USD | 7.67M USD |
| Gross profit | 111.17M USD | 101.87M USD | 108.81M USD | 97.5M USD | −332K USD |
| Research and development | 13.7M USD | 12.02M USD | 13.78M USD | 16.69M USD | 64.57M USD |
| Selling, general, and administrative | 85.98M USD | 73.62M USD | 75.82M USD | 71.61M USD | 18.82M USD |
| Operating expenses | 99.68M USD | 85.71M USD | 176.04M USD | 88.29M USD | 83.39M USD |
| Interest income | 1.75M USD | 1.55M USD | 1.04M USD | 726K USD | 39K USD |
| Depreciation and amortization | 2.48M USD | 1.59M USD | 1.11M USD | 1.13M USD | 290K USD |
| Operating income | 11.49M USD | 16.23M USD | −67.23M USD | 9.2M USD | −83.73M USD |
| Net income | 5.03M USD | 12.09M USD | −92.93M USD | 2.3M USD | −87.93M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$17.00
141.48% upside| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Jan 13, 2023 | $0.24Quarterly | Jan 5, 2023 | — |
Dividend | Sep 21, 2022 | $1.43Quarterly | Sep 6, 2022 | — |
Dividend | Aug 20, 2015 | $0.569Quarterly | — | — |
Ex-dividend Jan 13, 2023
$0.24
Quarterly
Record Jan 5, 2023
Ex-dividend Sep 21, 2022
$1.43
Quarterly
Record Sep 6, 2022
Ex-dividend Aug 20, 2015
$0.569
Quarterly
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI4.04M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2.72M0.00%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1.57M0.00%95.4B USD0.05%$235+0.80%
Schwab U.S. Small-Cap ETFSCHA1.25M0.01%21.82B USD0.03%$32.79+0.40%
Vanguard Russell 2000 ETFVTWO694.84K0.00%18B USD0.06%$112.66+0.50%
iShares Russell 2000 Growth ETFIWO671.45K0.00%13.92B USD0.24%$356.78+0.94%
WisdomTree U.S. SmallCap FundEES136.31K0.02%683.92M USD0.38%$65.48+0.06%
Schwab U.S. Broad Market ETFSCHB122.59K0.00%45.38B USD0.03%$29.91+0.61%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOWisdomTree U.S. SmallCap FundEESSchwab U.S. Broad Market ETFSCHBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
